Drugs / QLS-111-FDC
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2/3 | NCT07354516 | Mar → Jul 2026 overdue | ocular hypertension, open-angle glaucoma | Qlaris Bio, Inc. | Active not recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | QLS-111-FDC | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07354516 ↗ |
| Route | Topical | “administered by topical ophthalmic (TO) application” NCT07354516 ↗ |